First-pass extracted concept

MYH9

Candidate: concept label1 source documents3 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

myosin heavy chain 9

Extracted Explainers

What the tool is doing

The review presents MYH9 as a multifunctional factor in GI tumor biology associated with poor prognosis, invasion, and metastasis. It is discussed as a mechanistic node connected to survival, proliferation, and epithelial-mesenchymal transition.

Source 1DOI PubMed

What problem it solves

As a review focal point, MYH9 helps organize a broad literature on GI cancer progression and possible therapeutic intervention points.

Source 1DOI PubMed

What it does not solve

The provided abstract does not establish MYH9 itself as a collection-worthy engineered tool, delivery system, or assay method.

Source 1DOI PubMed

Alternatives

The abstract does not name alternative biomarkers or targets; it only frames MYH9 as one promising therapeutic target within GI oncology.

Source 1DOI PubMed

Evidence Snippets

Myosin heavy chain 9 (MYH9), a non-muscle myosin heavy chain protein, has been identified as a significant factor in gastrointestinal (GI) oncology...

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1review2025MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1disease associationsupports2025Source 1DOI PubMed

In gastrointestinal malignancies including esophageal, gastric, and colorectal cancers, MYH9 overexpression is associated with poor prognosis and with tumor invasion and metastasis.

Quoted textsource-backed

MYH9... has been identified as a significant factor in gastrointestinal (GI) oncology, with its overexpression in various GI malignancies such as esophageal, gastric, and colorectal cancers being associated with poor prognosis and playing a role in tumor invasion and metastasis.

Claim 2mechanistic pathway summarysupports2025Source 1DOI PubMed

The review links MYH9 to the PI3K/AKT/mTOR signaling axis in GI tumors, suggesting roles in cancer cell survival, proliferation, and epithelial-mesenchymal transition.

Quoted textsource-backed

The review synthesizes the current body of knowledge regarding MYH9's role in GI tumors, focusing on its molecular mechanisms, including its interaction with key signaling pathways like the phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin axis, which suggests a role in cancer cell survival, proliferation, and epithelial-mesenchymal transition.

Claim 3therapeutic potentialsupports2025Source 1DOI PubMed

The review describes MYH9 as a potential therapeutic target in GI tumors, with preclinical models reported to show inhibition of tumor growth and enhanced chemosensitivity when MYH9 is targeted.

Quoted textsource-backed

The review also explores MYH9's potential as a therapeutic target, with preclinical models demonstrating promising results in inhibiting tumor growth and enhancing chemosensitivity.